Diabetes and hypertension

Diabetes Care

Volumn 24, Issue 9, 2001, Pages 1679-1684

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANIMAL; CONFERENCE PAPER; DIABETES MELLITUS; HUMAN; HYPERTENSION; OBESITY; PATHOPHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION; OBESITY;

EID: 0035464207     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.9.1679     Document Type: Article

References (17)

1. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351:1755-1762, 1998
2. Birkenhager WH, Staessen JA, Gasowski J, de Leeuw PW: Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial. J Nephrol 13:232-237, 2000
3. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611-616, 1999
4. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
5. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
6. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 355:253-259, 2000
7. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285:2719-2728, 2000
8. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B: Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 103:1869-1874, 2000
9. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
10. Reisin E, Weir MR, Falkner B, Hutchinson HG, Anzalone DA, Tuck ML: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 30:140-145, 2000
11. Bloomgarden ZT: Perspectives on the news: dyslipidemia, endothelial dysfunction, and glycosylation. Diabetes Care 23: 690-698, 2000
12. Lansang MC, Osei SY, Coletti C, Krupinski J, Hollenberg NK: The mechanism of hyperglycemia-induced Ras activation: contribution of metabolic pathways (Abstract). In Proceedings of the 16th Annual Meeting of ASH. New York, ASH, 2001, p. 352
13. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000
14. Wheeldon NM, Viberti GC, for the MARVAL Trial: Microalbuminuria reduction with valsartan (Abstract). In Proceedings of the 16th Annual Meeting of the ASH. New York, ASH, 2001, OR6
15. Patel V, Panja S, Sailesh S, Kohner EM: Retinal perfusion pressure and pulse pressure: clinical parameters in predicting progression in diabetic retinopathy (Abstract). In Proceedings of the 16th Annual Meeting of the ASH. New York, ASH, 2001, OR17
16. Swislocki ALM, Noth RN, Volpp B, Siegel D: Prevalence of systolic hypertension in a diabetic population assessed by computer review (Abstract). In Proceedings of the 16th Annual Meeting of the ASH. New York, ASH, 2001, P499
17. Brook RD, Rubenfire M, Ridker P, Kehrer C, Rajagopalan S: Abdominal adiposity predicts endothelial dysfunction in uncomplicated obesity: an analysis of traditional and novel risk factors (Abstract). In Proceedings of the 16th Annual Meeting of the ASH. New York, ASH, 2001, OR3